Fort Washington Investment Advisors Inc. OH Has $25.32 Million Position in Progyny, Inc. (NASDAQ:PGNY)

Fort Washington Investment Advisors Inc. OH grew its stake in Progyny, Inc. (NASDAQ:PGNY) by 90.1% during the 4th quarter, HoldingsChannel reports. The firm owned 1,467,780 shares of the company’s stock after acquiring an additional 695,740 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Progyny were worth $25,319,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Quarry LP grew its stake in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after buying an additional 836 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after acquiring an additional 1,246 shares in the last quarter. Creative Planning grew its position in Progyny by 13.8% during the 2nd quarter. Creative Planning now owns 10,564 shares of the company’s stock worth $302,000 after acquiring an additional 1,283 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Progyny during the 2nd quarter valued at $44,000. Finally, Cetera Trust Company N.A raised its position in Progyny by 30.0% in the 3rd quarter. Cetera Trust Company N.A now owns 7,210 shares of the company’s stock valued at $121,000 after purchasing an additional 1,665 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction on Thursday, December 26th. The shares were purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Anevski acquired 209,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the transaction, the chief executive officer now owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $21.15 on Thursday. The company’s 50-day moving average price is $16.40 and its two-hundred day moving average price is $19.43. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08. The stock has a market capitalization of $1.80 billion, a PE ratio of 36.47, a price-to-earnings-growth ratio of 2.10 and a beta of 1.31.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period last year, the company posted $0.16 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. On average, analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PGNY has been the topic of several research analyst reports. Bank of America decreased their target price on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Progyny in a report on Tuesday, October 1st. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $17.00 target price (down from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Truist Financial reissued a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Finally, Barclays dropped their price objective on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.